Bruker stock adds a USD 6 million UC Berkeley order

Published on 10/06/2026 at 10:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bruker stock was trading at USD 63.72 on October 6, 2026, as new proteomics workflows and a UC Berkeley order exceeding USD 6 million sharpen the story. Q2 revenue rose 5.2 percent to USD 838.5 million.

BRKR, US1167941087, Illustration mit AI erstellt.

Bruker stock (ISIN US1167941087) was trading at USD 63.72 on Nasdaq at 1:57 p.m. ET on October 6, 2026, while the company added new proteomics workflows and a UC Berkeley order exceeding USD 6 million to its latest product story. The combination gives investors a concrete link between Bruker's instrument portfolio and demand from advanced research centers.

Research order exceeds USD 6 million

According to Bruker on September 21, 2026, the University of California, Berkeley placed a multi-system order for high-field NMR instruments exceeding USD 6 million, with delivery expected in 2027. The project centers on an 800 MHz-class spectrometer and supports chemistry, materials science and structural biology research.

Simply Wall St reported on October 5, 2026, that Bruker introduced new mass spectrometry and AI workflows for proteomics and nucleic acid research. Those launches expand the potential use of Bruker's hardware, software and analytical methods across drug discovery and disease biology.

Revenue rose while expectations split

Bruker's second-quarter 2026 revenue increased 5.2 percent year over year to USD 838.5 million, according to MarketBeat in its September 14, 2026 report. The same report said quarterly EPS of USD 0.49 exceeded the USD 0.38 consensus, while revenue fell short of the USD 853.57 million estimate.

Management maintained fiscal 2026 EPS guidance of USD 2.10-2.15, and the analyst estimate cited by MarketBeat was USD 2.12. The split matters: earnings execution was ahead of expectations, but revenue conversion remained the more demanding test for the next reporting cycle.

Analysts remain below the stock price

MarketBeat lists a Moderate Buy consensus from 14 analysts, including two Strong Buy ratings, six Buys, five Holds and one Sell. Its average target of USD 57.86 is USD 5.86 below the USD 63.72 Nasdaq price, while the published target range runs from USD 35.00 to USD 80.00.

The valuation debate is therefore tied to delivery rather than to a single product announcement. Bruker's current price is USD 3.26 below its 52-week high of USD 66.98, while the 52-week low is USD 32.37, giving the stock a wide USD 34.61 trading span.

Bruker stock holds near yearly high

Bruker stock was trading at USD 63.72 on Nasdaq on October 6, 2026, with a daily change of 0.76 percent, volume of 598,779 shares and a market capitalization of USD 9.7 billion. The next investor checkpoint is the conversion of the new research demand and proteomics expansion into revenue and margin progress.